developed by or licensed to the company. These and other risks are described in greater detail in the company's filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve the goals or plans described in its forward looking statements, and investors should not place undue Brooklyn Dodgers Hat New Era
About the CompanySafe Harbor Statement This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the risks and uncertainties associated with: conducting preclinical and clinical trials of the company's drug candidates that demonstrate these candidates' safety and effectiveness; obtaining regulatory approvals to conduct Adidas Hat For Kids
14 /PRNewswire FirstCall/ today announced that Dennis M. Keane, Chief Financial Officer has resigned from the Company effective December 24, 2004 to spend more time with his family. Mr. Keane will continue to work with the Company as a consultant through the completion of the Adidas Hat Company's year end 2004 audit. Joseph M. Donabauer, Controller and Principal Accounting Officer, has been appointed to Vice President, and will oversee the Company's finance functions until Mr. Keane's successor is named.
Roche (RHHBY) And GlaxoSmithKline (GSK) Release: New Drug Application Submitted To FDA For Intravenous Injection Of Boniva(TM)Cardinal Health (CAH) Announces Global Restructuring Plan To Accelerate Growth; Cardinal Health To Slash 4,200 Jobs
1 CFO Keane R
Mr. Donabauer has over 20 years of financial management experience. He has served as Memory Pharmaceuticals' Controller since 2002 and the Company's Principal Accounting Officer since December 2003. Prior to joining Memory Pharmaceuticals, Mr. Donabauer held senior financial management positions including Controller of the New Jersey operations at Genzyme Biosurgery (formerly Biomatrix Incorporated). Prior to joining Genzyme, Mr. Donabauer held financial management positions at Hoffman La Roche and Reckitt Colman (now Reckitt Benckiser).
"I want to thank Dennis for his many contributions to the Company," said Tony Scullion, Chief Executive Officer of Memory Pharmaceuticals. "I, Joe Donabauer and the rest of the Finance team, wish Dennis and his family all the best in the future."
clinical trials and to commercialize the company's drug candidates; the company's dependence on its collaborations with Roche and its license relationship with Bayer; the company's ability to enter into and maintain collaborations with third parties for its other early stage drug development programs; achieving milestones under the company's collaborations; obtaining additional financing to support the company's R and clinical activities and operations; the company's dependence on third party preclinical or clinical research organizations, manufacturers and consultants; and protecting the intellectual property Jordan Caps 2016
reliance on these statements. (MAXY) Announces New Development Program And Product Development Prioritization; Will Stop Further Development Of Its Interferon Beta ProgramMerck Co., Inc. (MRK) To Slash About 5,100 Jobs By Year's End, Will Cut Millions Of Dollars In Spending
Chicago Cubs Hats
Atlanta Braves Hat New Era
Ny Hats Grey
Gucci Belt All Red
Louis Vuitton Belt Expensive
Nike Cap Green
Jordan Caps Red
New Era Hats Ny
New Era Snapbacks Black
Lv Belt White
Nike Cap For Men
Adidas Cap Camo
New Era Caps White
Gucci Belt All White
Lv Belts Online